Palladio Biosciences

Palladio Biosciences, Inc., is a Centessa company. Their first product, lixivaptan, is in Phase 3 clinical development for the treatment of autosomal polycystic kidney disease (ADPKD). ADPKD causes numerous fluid-filled cysts to grow in both kidneys. It is a life-limiting, chronic and progressive d... Read more